 This is a Phase 1, randomized, open-label, 4-way crossover pharmacokinetic PK and pharmacodynamic PD study in healthy adult male subjects designed to assess the relative bioavailability of RDEA3170 2.5 mg tablets administered as a 10 mg dose 2.5 mg × 4 tablets and of a single RDEA3170 10 mg tablet. This study will also assess the effect of a low-fat and high-fat meal on the PK and PD of RDEA3170 10 mg tablets. 